Analysis of clinicopathological and cytogenetic differences between B-lymphoblastic lymphoma and B-lymphoblastic leukemia in childhood.

abstract：:Bone marrow transplantation procedure has emerged as an effective treatment for hematological malignancies. However, recurrence of leukemia is still the major cause of treatment failure. Subsequent treatment in this category of patients, generally considered incurable, has not been yet standardized. At our institution...

journal_title：Leukemia & lymphoma

authors： Sica S,Salutari P,Di Mario A,D'Onofrio G,Etuk B,Leone G

更新日期：1994-09-01 00:00:00

abstract：:The transcriptional factor SOX11 is a disease-defining antigen in mantle cell lymphoma (MCL) and absent in most non-malignant tissues. To explore the role of SOX11-related cell signaling, and potentially take benefit from these for targeted therapy, associated networks and proteins need to be defined. In this study, w...

journal_title：Leukemia & lymphoma

authors： Kuci V,Nordström L,Conrotto P,Ek S

更新日期：2016-08-01 00:00:00

abstract：:We studied a series of 68 subjects diagnosed with childhood acute myeloid leukemia (AML) using conventional cytogenetics and fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR) to analyze mutations in FLT3 and NPM1 genes, and/or array comparative genomic hybridization (CGH). Cytogenetic/FISH abn...

journal_title：Leukemia & lymphoma

authors： Armengol G,Canellas A,Alvarez Y,Bastida P,Toledo JS,Pérez-Iribarne Mdel M,Camós M,Tuset E,Estella J,Coll MD,Caballín MR,Knuutila S

更新日期：2010-01-01 00:00:00

abstract：:One of the possible causes of treatment failure in acute leukemia is the emergence of multidrug resistance caused by P-glycoprotein (P-gp) overexpression. We compared a flow cytometric assay using JC-1 with a technique using rhodamine 123 (rho123) to evaluate the P-gp function in acute leukemia. Samples from 50 acute ...

journal_title：Leukemia & lymphoma

authors： Swerts K,de Moerloose B,Dhooge C,Noens L,Laureys G,Benoit Y,Philippé J

更新日期：2004-11-01 00:00:00

abstract：:A patient with primary biliary cirrhosis (PBC) who developed idiopathic myelofibrosis (IM) is reported. The initial diagnosis of PBC was established by liver biopsy, performed after a 2-month history of constitutional symptoms associated with abnormalities of the serum liver enzymes, with typical serum immunological m...

journal_title：Leukemia & lymphoma

authors： Hernández-Boluda JC,Jiménez M,Rosiñol L,Cervantes F

更新日期：2002-03-01 00:00:00

abstract：:Infection with the Epstein-Barr virus (EBV) is common worldwide. A significant number of infected individuals develop infectious mononucleosis (IM). IM is manifested in most patients as a benign disease with mild symptoms. However, serious complications may develop in a subset of patients. Because EBV-infected B lymph...

journal_title：Leukemia & lymphoma

authors： Wright-Browne V,Schnee AM,Jenkins MA,Thall PF,Aggarwal BB,Talpaz M,Estrov Z

更新日期：1998-08-01 00:00:00

abstract：:We have identified a family in which three members developed B-cell lymphoproliferative disorders within a nine month period. The 33 year old proband and his mother have hairy cell leukemia, and his 37 year old brother developed a large cell lymphoma. Chromosomal fragile site analysis of peripheral blood lymphocytes o...

journal_title：Leukemia & lymphoma

authors： Moormeier JA,Neilly ME,Vardiman JW,Le Beau MM,Golomb HM

更新日期：1991-01-01 00:00:00

abstract：:The myelodysplastic syndromes (MDS) are a heterogeneous group of disorders of hematopoiesis entailing hyperproliferative and ineffective hematopoiesis resulting in refractory cytopenia(s), and increased risk of transformation into acute myeloblastic leukemia (AML). The widely used classification defined by the French-...

journal_title：Leukemia & lymphoma

authors： Sawada K

更新日期：1994-06-01 00:00:00

abstract：:The hypomethylating agents azacitidine and decitabine are standard therapy for myelodysplastic syndromes (MDS), and are often used to treat patients with acute myeloid leukemia (AML) unlikely to benefit from cytotoxic chemotherapy. Switching hypomethylating agents after treatment failure is common, but this approach i...

journal_title：Leukemia & lymphoma

authors： Duong VH,Bhatnagar B,Zandberg DP,Vannorsdall EJ,Tidwell ML,Chen Q,Baer MR

更新日期：2015-06-01 00:00:00

abstract：:The G protein-coupled receptor (GPCR) CXCR4 is involved in bone marrow tropism and survival of chronic lymphocytic leukemia (CLL) cells. The function of the GPCRs cysteinyl leukotriene receptor 1 (CysLT1) and CysLT2 remains elusive. Here we demonstrate that in CLL and normal B lymphocytes, CysLT1 mRNA is consistently ...

journal_title：Leukemia & lymphoma

authors： Drost AC,Seitz G,Boehmler A,Funk M,Norz KP,Zipfel A,Xue X,Kanz L,Möhle R

更新日期：2012-04-01 00:00:00

abstract：:Fas-ligand (FasL) is a member of the tumor necrosis factor family and transmits apoptotic cell death signal by binding to its receptor, Fas. FasL is expressed on the cell surface of activated T-cell and natural killer (NK) cell. It has been shown that the FasL can be released from the cell surface by metalloproteinase...

journal_title：Leukemia & lymphoma

authors： Kanda Y,Chiba S,Tanaka Y,Kami M,Saito T,Izutsu K,Asai T,Yuji K,Ogawa S,Honda H,Mitani K,Usuki K,Urabe A,Shirakawa K,Yatomi T,Nakamura N,Yazaki Y,Hirai H

更新日期：1999-08-01 00:00:00

abstract：:Recent advances in genomics are revealing new molecular targets for vaccination strategies in cancer, and unraveling the immune pathways that must be activated. Initially, work focused on idiotypic antigen expressed by the clonal immunoglobulin (Ig) of B-cell tumors. This involved assembling the encoding V(H) and V(L)...

journal_title：Leukemia & lymphoma

authors： Stevenson FK,King A,Ottensmeier CH

更新日期：2003-01-01 00:00:00

abstract：:Eighteen patients (pts) with myelodysplastic syndrome (MDS) were treated with thymopentin (TP) (50 mg subcutaneously for 5 days) and recombinant interferon alpha 2a (rIFN alpha 2a) (3 MU/m2 subcutaneously on the sixth day); the courses were delivered every week. Moreover those pts with > or = 10% blasts in the bone ma...

journal_title：Leukemia & lymphoma

authors： Venditti A,Scimò MT,del Poeta G,Buccisano F,Stasi R,Mastino A,Grelli S,Favalli C,Garaci E,Papa G

更新日期：1995-01-01 00:00:00

abstract：:This study investigated the prognostic factors of Castleman disease (CD) and focused specifically on multicentric CD (MCD). Seventy patients with CD were studied. Forty-three patients (61.5%) had unicentric CD (UCD) and 27 patients (38.5%) had MCD. Thirty-six patients with UCD (83.7%) underwent surgical excision, and ...

journal_title：Leukemia & lymphoma

authors： Shin DY,Jeon YK,Hong YS,Kim TM,Lee SH,Kim DW,Kim I,Yoon SS,Heo DS,Park S,Kim BK

更新日期：2011-08-01 00:00:00

abstract：:Thymosin β4 (Tβ4) was originally isolated as a thymic hormone from calf thymosin fraction 5 which exhibited both immune and endocrine functions in vivo and in vitro. Tβ4 is a ubiquitous peptide located in various tissues of mammalian species and other vertebrate classes. Recent studies on the molecular cloning and seq...

journal_title：Leukemia & lymphoma

authors： Kudo J,Shimamura R,Ishibashi H,Niho Y

更新日期：1991-01-01 00:00:00

abstract：:The Rai and Binet staging systems, which are used as standard methods for evaluating the prognosis of chronic lymphocytic leukemia (CLL), have some restrictions in identifying patients with early-stage CLL who will progress rapidly. To solve this defect, other prognostic parameters have become important in recent year...

journal_title：Leukemia & lymphoma

authors： Hancer VS,Kose M,Diz-Kucukkaya R,Yavuz AS,Aktan M

更新日期：2011-01-01 00:00:00

abstract：:Because of the lack of standard treatment in refractory and relapsed acute myelogenous leukemia (AML) several new drugs have been employed alone to evaluate their efficacy in this peculiar category of patient. Bisantrene, a new anthracene bishydrazone derivative, has shown antileukemic effect in phase I and II clinica...

journal_title：Leukemia & lymphoma

authors： Spadea A,Petti MC,Aloespiriti MA,Avvisati G,De Gregoris C,Fazi P,Latagliata R,Amadori S,Mandelli F

更新日期：1993-02-01 00:00:00

abstract：:The epidemiology of splenic marginal zone lymphoma (SMZL) in the United States has not been addressed. Eight years of data (2001-2008) from 17 registries of the Surveillance, Epidemiology and End Results (SEER) program were used for this study. Of the 116,411 cases of non-Hodgkin lymphoma (NHL) in the registries, 763 ...

journal_title：Leukemia & lymphoma

authors： Liu L,Wang H,Chen Y,Rustveld L,Liu G,Du XL

更新日期：2013-07-01 00:00:00

abstract：:We have analyzed the co-expression of the bcr-abl and HoxA9 genes in the follow-up of patients with chronic myeloid leukemia (CML). In the present work we measured the HoxA9 and bcr-abl gene expression in sequential samples. In all patients, bcr-abl and HoxA9 were expressed at detectable levels in every sample. When t...

journal_title：Leukemia & lymphoma

authors： Tedeschi FA,Cardozo MA,Valentini R,Zalazar FE

更新日期：2010-05-01 00:00:00

abstract：:Hairy cell leukemia (HCL), a rare haematological disorder of B-cell origin, mainly presents with bone marrow infiltration, haematopoietic insufficiency, and splenomegaly. In some cases, osteolytic lesions can be observed. Many of these clinical features, especially haematopoietic insufficiency and osteolytic lesions a...

journal_title：Leukemia & lymphoma

authors： Schmid M,Porzsolt F

更新日期：1995-05-01 00:00:00

abstract：:Primary myelosarcomas, also called leukemia cutis, granulocytic sarcomas or chloromas, are rare extramedullary manifestations of acute myeloid leukemia (AML) which precede bone marrow involvement. Skin infiltration was the most frequent localization associated with a myelomonocytic differentiation. Although first remi...

journal_title：Leukemia & lymphoma

authors： Reinhardt D,Creutzig U

更新日期：2002-03-01 00:00:00

abstract：:The prognostic value of positron emission tomography (PET) in early therapy response assessment, after completion of chemotherapy and 3 months after the end of treatment in advanced Hodgkin lymphoma (HL) remains to be defined. We report the results of 69 patients with first presentation of advanced HL. [18F]-fluoro-2-...

journal_title：Leukemia & lymphoma

authors： Markova J,Kahraman D,Kobe C,Skopalova M,Mocikova H,Klaskova K,Dedeckova K,Eich HT,Böll B,Dietlein M,Kozak T

更新日期：2012-01-01 00:00:00

abstract：:Thalidomide is thought to have anti-angiogenic and immunomodulatory properties, including suppression of tumor necrosis factor-alpha, effects on interleukins and interferons, down-regulation of some cell adhesion molecules, and changes in the proportion of lymphocyte subsets. It is unclear whether the clinical respons...

journal_title：Leukemia & lymphoma

authors： Strupp C,Germing U,Aivado M,Kündgen A,Fenk R,Hünerlitürkoglu A,Kobbe G,Haas R,Gattermann N

更新日期：2005-07-01 00:00:00

abstract：:We have compared the effects of AcSDKP, Thymosin beta4 (Tbeta4), MIP1alpha and TGFbeta on acute myeloid leukemia (AML) and B-lineage acute lymphoid leukemia (B-ALL) cells using liquid cultures in the presence of GM-CSF, IL-3 and SCF for AML cells and IL-3 and IL-7 for ALL cells. Each molecule was added daily and cell ...

journal_title：Leukemia & lymphoma

authors： Defard M,Lemoine FM,Bonnet ML,Baillou C,Isnard F,Najman A,Guigon M

更新日期：1997-11-01 00:00:00

abstract：:We have studied the functional properties of topoisomerase II (Topo II) in a subclone of the HL-60 cell line, which is highly resistant to cytotoxic Topo II inhibitors, but does not express p-glycoprotein. The cells contain the two forms of human topo II with Mr 170 and 180 kDa in equal proportions. Two different stat...

journal_title：Leukemia & lymphoma

authors： Boege F,Gieseler F,Biersack H,Meyer P

更新日期：1993-03-01 00:00:00

abstract：:Autocrine Motility Factor (AMF)/maturation factor (MF)/neuroleukin (NLK) is a multifunctional protein, which acts as a glucose 6-phosphate isomerase (G6PI) intracellularly. Exto-G6PI stimulates invasion and metastasis of tumor cells, neurotropic growth and differentiation of leukemic cells. The cell motility and proli...

journal_title：Leukemia & lymphoma

authors： Haga A,Komazaki S,Funasaka T,Hashimoto K,Yokoyama Y,Watanabe H,Raz A,Nagase H

更新日期：2006-10-01 00:00:00

abstract：:A novel cultured cell line, NCU-L-1, was established from a 71-year-old Japanese woman with acute lymphoblastic leukemia, L3 FAB, Burkitt's type. The NCU-L-1 cells were shown to have a mature B-cell phenotype on the basis of immunologic surface marker analysis; including IgG Lambda surface immunoglobulins, CD19, CD20 ...

journal_title：Leukemia & lymphoma

authors： Nitta M,Iwaki O,Wakita A,Kodama H,Takeuchi G,Takada K,Mitomo Y,Yamamoto M,Amano M,Murate T,Koike K,Osada H,Ueda R,Shamoto M

更新日期：1990-01-01 00:00:00

abstract：:According to the International Workshop on Chronic Lymphocytic Leukemia/National Institutes of Health (iwCLL/NIH) guidelines for the diagnosis and treatment of chronic lymphocytic leukemia (CLL), bone marrow biopsy (BMB) is not required at diagnosis, however recommended before initiating treatment. That notwithstandin...

journal_title：Leukemia & lymphoma

authors： Baliakas P,Kanellis G,Stavroyianni N,Fameli M,Anagnostopoulos A,Stamatopoulos K,Papadaki T

更新日期：2013-11-01 00:00:00

abstract：:Nearly ten years of research on the feasibility of specific immunotherapy targeting the junctional regions of BCR-ABL has considerably increased our knowledge of which MHC alleles might present BCR-ABL peptides, yet has failed to provide us with definite proof of appropriate processing of the hybrid oncoprotein into s...

journal_title：Leukemia & lymphoma

authors： Leeksma OC,Kessler JH,Huijbers IJ,Ten Bosch GJ,Melief CJ

更新日期：2000-06-01 00:00:00

abstract：:High-dose therapy (HDT) is now recommended for patients under 60 years of age with chemosensitive relapsed aggressive non-Hodgkin's lymphoma. However, approximately half of these patients will be cured by HDT. Prognostic factors are needed to predict which patients with chemosensitive lymphoma to second-line therapy c...

journal_title：Leukemia & lymphoma

authors： Jabbour E,Peslin N,Arnaud P,Ferme C,Carde P,Vantelon JM,Bocaccio C,Bourhis JH,Koscielny S,Ribrag V

更新日期：2005-06-01 00:00:00